OncoSec Presents Two Late-Breaking Abstracts on TAVO-PLUS at the American Association for Cancer Research (AACR) Virtual Annual Meeting II Jun 22, 2020 9:05am EDT
OncoSec Expands KEYNOTE-890 Trial into First-Line Metastatic Triple Negative Breast Cancer (mTNBC) with TAVO™ and KEYTRUDA® Plus Chemotherapy Jun 09, 2020 9:00am EDT
OncoSec Strengthens IP Portfolio with Three New Patents Covering TAVO™ and Its Electroporation Gene Delivery System May 27, 2020 9:00am EDT
OncoSec to Present Two Late-Breaking Pre-Clinical Abstracts on TAVO-PLUS at the American Association for Cancer Research (AACR) Virtual Annual Meeting II May 21, 2020 9:00am EDT
OncoSec Partners with the Melanoma Research Foundation to Host Live Panel Discussion during Melanoma Awareness Month May 14, 2020 9:00am EDT
OncoSec's TAVO™ Receives ATMP Certification from European Medicines Agency to Support Marketing Authorization Application in Metastatic Melanoma May 13, 2020 9:18am EDT
OncoSec's TAVO™ in Combination with KEYTRUDA® Demonstrated 41% Overall Response Rate and 36% Complete Response in a Late-Stage Metastatic Melanoma Study Featured in 'Clinical Cancer Research' May 06, 2020 9:00am EDT
OncoSec Presents Pre-Clinical Data from Its Visceral Lesion Applicator (VLA) and APOLLO Feasibility Study Demonstrating TAVO™ Can Be Safely Delivered and Electroporated in Liver at the Online Society of Interventional Radiology Annual Meeting Apr 21, 2020 9:00am EDT
OncoSec Appoints Renowned Oncologist and Immunologist, Herbert Kim Lyerly, M.D., Duke University, to its Board of Directors Apr 20, 2020 9:00am EDT
